Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.44 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.44 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27933293 | 0.97 | ALDH1A1 (0.65) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL14387492 | 0.94 | ALDH1A1 (0.59) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL25062001 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL16760877 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28493 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL12269194 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP4F2 | |
| SCHEMBL22845360 | 0.82 | CYP3A4 (0.50) | ALDH1A1CYP1A1CYP1B1CYP3A4CA1 | |
| SCHEMBL15936165 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| SCHEMBL12269074 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL28557531 | 0.79 | ALDH1A1 (0.92) | ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | BIOARDIS LLC | 2022-06-02 | — | — | US | disclosed |
| EP-3995491-A1 | COMPOUND, POLYMER, ORGANIC MATERIAL, AND OPTICAL DEVICE, OPTICAL COMPONENT, AND IMAGE DISPLAY DEVICE ALL INCLUDING SAID ORGANIC MATERIAL | Sony Group Corporation (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3184521-B1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-103804196-B | Star-shaped adamantane derivative molecular glass and preparation method and application thereof | 中国科学院理化技术研究所 | 2016-08-31 | — | — | CN | disclosed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2012031358-A1 | BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-15 | — | — | WO | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009023335-A2 | CARBAZOLYL POLYMERS FOR ORGANIC ELECTRONIC DEVICES | GENERAL ELECTRIC COMPANY (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | FGFR4, FGFR3, FGFR1 | ALDH1A1 876/4885CYP1A1 964/4885CYP1B1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.